{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-234808","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2024-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.169742+00:00","generated_at":"2026-05-30T17:22:40.886623+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"UroGen Pharma appoints Christopher Degnan as CFO; Don Kim resigns effectively Oct 8, 2024","bullets":["Don Kim resigned as CFO, principal financial and accounting officer effective Oct 8, 2024; will provide part-time consulting through Apr 28, 2025 for $36,260.","Kim receives 9 months base salary continuation, $217,590 lump sum (2024 target bonus), and COBRA reimbursement for 9 months.","Christopher Degnan appointed CFO effective Oct 8; prior CFO of Galera Therapeutics and Verrica Pharmaceuticals.","Degnan receives $500,000 annual base salary, 50% target bonus, and inducement equity: option for 74,142 shares at $13.11 and 13,450 RSUs vesting over 3 years.","Severance terms for Degnan include 6 months base salary, pro-rata bonus, and accelerated vesting of 8.33% of equity on qualifying termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-234808","json":"https://secwatch.observer/filing/0001193125-24-234808.json","markdown":"https://secwatch.observer/filing/0001193125-24-234808.md","text":"https://secwatch.observer/filing/0001193125-24-234808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524234808/0001193125-24-234808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524234808/d838231d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:22:40.886623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a222864f0d","claim":"Don Kim resigned as Chief Financial Officer at UroGen Pharma Ltd..","evidence_excerpt":"pursuant to which Mr. Kim resigned from his positions as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective October 8, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524234808/0001193125-24-234808-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c190a8516f","claim":"Christopher Degnan was appointed as Chief Financial Officer at UroGen Pharma Ltd..","evidence_excerpt":"the Company appointed Christopher Degnan as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective on the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524234808/0001193125-24-234808-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}